Add to ORKGThe prevention of symptomatic heart failure co-incides with the treatment of patients in stage A and B of the AHA/ACC heart failure classification, in which symptoms are absent [1]. Thus the issue of this paper is to review the usefulness of betablock-ers in preventing the progression towards sympto-matic heart failure in Stage A and B
Chronic heart failure (CHF) today is a heart condition with the least favourable prognosis. Over the...
Background . Medical management of heart failure with preserved ejection fraction (HFPEF) remains u...
To adequately address the burden imposed by heart failure, a combined approach to prevention, early ...
The prevention of symptomatic heart failure represents the treatment of patients in the A and B stag...
Despite the fact that betablockers (BBs) are one of the main groups of therapy of patients with acut...
For a long time beta-blockers were considered contraindicated for use in heart failure although some...
Despite the fact that betablockers (BBs) are one of the main groups of therapy of patients with acut...
The introduction of blockers of beta-adrenergic receptors (beta-blockers – BB) in the clinical pract...
A recent individual patient data meta-analysis has shown that beta-blockers reduce mortality in pati...
Abstract: Heart failure (HF) is an epidemic associated with significant morbidity and mortality, aff...
Heart failure is a complex syndrome affecting several organs including kidney, lungs, liver, brain m...
heart failure, or asymptomatic left ventricular dysfunction (ALVD) are at high risk for developing s...
Beta-blocking agents have been shown to reduce the risk of hospitalization and death in patients wit...
Background/Aims Beta-blockers (BBs) have been shown to improve clinical outcomes in heart failure (H...
The use of beta-blocking agents in patients with heart failure is still controversial. An activated ...
Chronic heart failure (CHF) today is a heart condition with the least favourable prognosis. Over the...
Background . Medical management of heart failure with preserved ejection fraction (HFPEF) remains u...
To adequately address the burden imposed by heart failure, a combined approach to prevention, early ...
The prevention of symptomatic heart failure represents the treatment of patients in the A and B stag...
Despite the fact that betablockers (BBs) are one of the main groups of therapy of patients with acut...
For a long time beta-blockers were considered contraindicated for use in heart failure although some...
Despite the fact that betablockers (BBs) are one of the main groups of therapy of patients with acut...
The introduction of blockers of beta-adrenergic receptors (beta-blockers – BB) in the clinical pract...
A recent individual patient data meta-analysis has shown that beta-blockers reduce mortality in pati...
Abstract: Heart failure (HF) is an epidemic associated with significant morbidity and mortality, aff...
Heart failure is a complex syndrome affecting several organs including kidney, lungs, liver, brain m...
heart failure, or asymptomatic left ventricular dysfunction (ALVD) are at high risk for developing s...
Beta-blocking agents have been shown to reduce the risk of hospitalization and death in patients wit...
Background/Aims Beta-blockers (BBs) have been shown to improve clinical outcomes in heart failure (H...
The use of beta-blocking agents in patients with heart failure is still controversial. An activated ...
Chronic heart failure (CHF) today is a heart condition with the least favourable prognosis. Over the...
Background . Medical management of heart failure with preserved ejection fraction (HFPEF) remains u...
To adequately address the burden imposed by heart failure, a combined approach to prevention, early ...